The global end stage renal disease market size is calculated at USD 135.47 billion in 2024, grew to USD 153.72 billion in 2025 and is predicted to reach around USD 479.36 billion by 2034, expanding at a CAGR of 13.47% between 2024 and 2034. The Asia Pacific end stage renal disease market size accounted for USD 52.83 billion in 2024 and is representing a notable CAGR of 13.61% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: End Stage Renal Disease Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. End Stage Renal Disease Market, by Treatment Type, 2024-2034
8.1.1. Transplant
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Dialysis
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. North America
9.1.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1. Nipro Corp.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Fresenius Medical Care AG & Co. KGaA
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Baxter International, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Medtronic Plc
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. B. Braun Melsungen AG
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. BD
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Asahi Kasei Medical Co., Ltd.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Cantel Medical
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Nikkiso Co., Ltd.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. JMS Co. Ltd.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample